← All companies

RCUS

Arcus Biosciences, Inc.

RCUS NYSE Pharmaceutical Preparations EDGAR ↗

$27.62

-0.57 -2.02%

Key statistics

from XBRL data in SEC filings

Market cap

$3.47B

Revenue (TTM)

$32.0M

Net income (TTM)

-$369M

EPS (TTM)

$-3.17

P/E ratio

—

Dividend yield

—

Free cash flow

-$484M

Cash

$201M

Total assets

$997M

Gross margin

—

52-week range

$8.88 – $31.74

Recent SEC filings

40 most recent

Annual, quarterly & current reports

8-K Shareholder vote results Jun 12, 2026 10-Q Quarter ended 2026-03-31 May 5, 2026 8-K Results of operations (earnings release) May 5, 2026 8-K Other events Apr 20, 2026 8-K Director or officer change Mar 23, 2026 10-K Fiscal year ended 2025-12-31 Feb 25, 2026 8-K Results of operations (earnings release) Feb 25, 2026 8-K Entered a material agreement; Took on a direct financial obligation Dec 18, 2025 8-K Other events Dec 12, 2025 8-K Other events Nov 3, 2025 10-Q Quarter ended 2025-09-30 Oct 28, 2025 8-K Results of operations (earnings release) Oct 28, 2025 8-K Other events Oct 14, 2025 8-K Other events Oct 6, 2025 10-Q Quarter ended 2025-06-30 Aug 6, 2025 8-K Results of operations (earnings release) Aug 6, 2025 8-K Shareholder vote results; Other events Jun 12, 2025 8-K Regulation FD disclosure; Other events Jun 2, 2025 10-Q Quarter ended 2025-03-31 May 6, 2025 8-K Results of operations (earnings release) May 6, 2025 10-K Fiscal year ended 2024-12-31 Feb 25, 2025 8-K Results of operations (earnings release) Feb 25, 2025 8-K Other events Feb 19, 2025 8-K Results of operations (earnings release); Other events Feb 18, 2025 8-K Director or officer change Feb 6, 2025 8-K Director or officer change Jan 21, 2025 10-Q Quarter ended 2024-09-30 Nov 6, 2024 8-K Results of operations (earnings release) Nov 6, 2024 8-K Regulation FD disclosure; Other events Oct 24, 2024 8-K Entered a material agreement; Took on a direct financial obligation Aug 27, 2024 10-Q Quarter ended 2024-06-30 Aug 8, 2024 8-K Results of operations (earnings release) Aug 8, 2024 8-K Shareholder vote results; Other events Jun 6, 2024 8-K Regulation FD disclosure; Other events Jun 3, 2024 8-K Other events May 23, 2024 10-Q Quarter ended 2024-03-31 May 8, 2024 8-K Results of operations (earnings release) May 8, 2024 10-K Fiscal year ended 2023-12-31 Feb 21, 2024 8-K Results of operations (earnings release) Feb 21, 2024 8-K Entered a material agreement; Unregistered sale of equity; Director or officer change; Other events Jan 30, 2024